What is the survival rate for cervical cancer stage IIIB?

The 5-year survival rate of stage IIIB cervical cancer is about 40%-60%, which is specifically related to the degree of tumor differentiation, treatment methods and individual differences.

Cervical cancer stage IIIB is locally advanced. The tumor has invaded the lower vagina or pelvic wall but has not spread to distant organs. According to the staging standards of the International Federation of Obstetrics and Gynecology, patients in this stage receive concurrent radiotherapy and chemotherapy as the main treatment method. External radiation combined with intracavitary brachytherapy, combined with chemotherapy drugs such as cisplatin, can significantly improve the local control rate. Radiotherapy techniques such as intensity-modulated radiotherapy can accurately target lesions and reduce damage to surrounding tissues. Some patients may require auxiliary surgery to remove residual lesions, and postoperative pathological evaluation can further guide subsequent treatment. During treatment, blood routine, liver and kidney function need to be monitored regularly, and adverse reactions such as radiation enteritis and bone marrow suppression need to be dealt with in a timely manner.

It is recommended that patients maintain a balanced diet on the basis of standardized treatment, appropriately supplement high-quality protein such as fish and soy products, and avoid spicy and irritating foods. Carry out soothing exercises such as walking and yoga according to your physical condition and maintain a normal schedule. Long-term follow-up is required after treatment, with HPV testing and imaging examinations reviewed every 3-6 months, and attention should be paid to signs of vaginal stump recurrence or distant metastasis. Psychological support is equally important, and anxiety can be alleviated through professional consultation or mutual help among patients.